Jane Qian

530 total citations
16 papers, 263 citations indexed

About

Jane Qian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jane Qian has authored 16 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jane Qian's work include PARP inhibition in cancer therapy (10 papers), Lung Cancer Research Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). Jane Qian is often cited by papers focused on PARP inhibition in cancer therapy (10 papers), Lung Cancer Research Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). Jane Qian collaborates with scholars based in United States, Canada and Australia. Jane Qian's co-authors include Kyle D. Holen, Minesh P. Mehta, Vincent L. Giranda, Hao Xiong, Ebenezer A. Kio, Qin Qin, Pierre Chabot, David Ball, Martin Dunbar and Te‐Chun Hsia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Jane Qian

16 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Qian United States 7 206 132 92 31 29 16 263
Lucy Scott United Kingdom 5 165 0.8× 253 1.9× 25 0.3× 14 0.5× 25 0.9× 8 355
Lucy A. Young United Kingdom 7 181 0.9× 204 1.5× 26 0.3× 14 0.5× 15 0.5× 9 264
Francesca Vena United States 4 176 0.9× 203 1.5× 70 0.8× 15 0.5× 12 0.4× 4 295
Paola Francica Switzerland 10 124 0.6× 158 1.2× 57 0.6× 6 0.2× 18 0.6× 14 249
Orsolya Rusz Hungary 10 197 1.0× 144 1.1× 118 1.3× 16 0.5× 53 1.8× 19 317
Hannah Dry United Kingdom 6 166 0.8× 143 1.1× 45 0.5× 20 0.6× 12 0.4× 12 295
Harriet Southgate United Kingdom 4 131 0.6× 230 1.7× 34 0.4× 21 0.7× 15 0.5× 4 288
Michał Marek Hoppe Singapore 5 171 0.8× 165 1.3× 52 0.6× 7 0.2× 35 1.2× 9 263
Andrea E. Wahner-Hendrickson United States 4 302 1.5× 118 0.9× 82 0.9× 7 0.2× 46 1.6× 6 363

Countries citing papers authored by Jane Qian

Since Specialization
Citations

This map shows the geographic impact of Jane Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Qian more than expected).

Fields of papers citing papers by Jane Qian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Qian. The network helps show where Jane Qian may publish in the future.

Co-authorship network of co-authors of Jane Qian

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Qian. A scholar is included among the top collaborators of Jane Qian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Qian. Jane Qian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Chabot, Pierre, Te‐Chun Hsia, Jeong‐Seon Ryu, et al.. (2016). Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology. 131(1). 105–115. 73 indexed citations
2.
Mehta, Minesh P., Ding Wang, Fen Wang, et al.. (2015). Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology. 122(2). 409–417. 75 indexed citations
3.
Mizugaki, Hidenori, Noboru Yamamoto, Hiroshi Nokihara, et al.. (2015). A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology. 76(5). 1063–1072. 26 indexed citations
4.
Han, Hyo S., Véronique Dièras, Michael Friedländer, et al.. (2015). Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology. 33(28_suppl). 155–155. 9 indexed citations
5.
Puhalla, Shannon, Hyo S. Han, Véronique Dièras, et al.. (2015). Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology. 33(15_suppl). TPS1102–TPS1102. 2 indexed citations
6.
Chabot, Pierre, Jeong‐Seon Ryu, В. А. Горбунова, et al.. (2015). Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). 2021–2021. 3 indexed citations
7.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2015). Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.. Journal of Clinical Oncology. 33(15_suppl). 8038–8038. 2 indexed citations
8.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2014). A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(5). S4–S5. 3 indexed citations
9.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2014). A Randomized, Double-Blind, Phase 2 Trial of Veliparib (Abt-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer. Annals of Oncology. 25. iv431–iv431. 6 indexed citations
10.
11.
Posadas, Edwin M., Nizar M. Tannir, Marc S. Ernstoff, et al.. (2011). Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy.. Journal of Clinical Oncology. 29(15_suppl). 2543–2543. 3 indexed citations
12.
Middleton, Mark R., Philip Friedlander, Oday Hamid, et al.. (2011). Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma. European Journal of Cancer. 47. 8–8. 4 indexed citations
13.
Rudin, Charles M., Ann M. Mauer, Martin Šmakal, et al.. (2011). Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(8). 1075–1082. 42 indexed citations
14.
Tannir, Nizar M., Christian Kollmannsberger, Marc S. Ernstoff, et al.. (2010). Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.. Journal of Clinical Oncology. 28(15_suppl). 4527–4527. 6 indexed citations
15.
Rugo, H. S., et al.. (2009). ABT-869 in Combination with Paclitaxel (P) as First-Line Treatment in Patients (Pts) with Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 5076–5076. 3 indexed citations
16.
Wong, Shekman, et al.. (1998). Lack of Cytochrome P450 1A2 Interaction Effect of ABT-761 on the Pharmacokinetics of Theophylline. American Journal of Therapeutics. 5(5). 303–306. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucy Scott Breakdown of academic impact, for papers by Lucy A. Young Breakdown of academic impact, for papers by Francesca Vena Breakdown of academic impact, for papers by Paola Francica Breakdown of academic impact, for papers by Orsolya Rusz Breakdown of academic impact, for papers by Hannah Dry Breakdown of academic impact, for papers by Harriet Southgate Breakdown of academic impact, for papers by Michał Marek Hoppe Breakdown of academic impact, for papers by Andrea E. Wahner-Hendrickson
Rankless by CCL
2026